Experimental mRNA injection takes on tough cancers

NCT ID NCT07040943

Completed Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This early-stage trial tests a new mRNA-based drug called IL-22BP in 6 adults with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and can shrink cancer. The study focuses on safety and tumor response, not a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IL-22BP mRNA injection
What this could lead to: If it works, this could point toward a new treatment option for patients with hard-to-treat solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 6 participants, so it is too small to prove effectiveness. The main goal is safety, and there is no guarantee the treatment will shrink tumors or work for others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERLEUKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INTERLEUKIN MRNA VACCINE REFRACTORY MALIGNANT SOLID TUMORS

Contacts and locations

Locations

Department of Radiation Oncology

Chengdu, Sichuan, 610000, China
West China Hospital of Sichuan University

Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.